Amgen Inc vs. X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals, Inc. Common Stock (XFOR) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| AMGN | XFOR | |
|---|---|---|
| Market Cap | $212.56 billion | $347.51 million |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | — |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AMGN | XFOR | |
|---|---|---|
| P/E Ratio | 24.42 | — |
| Price / Book | 18.19 | 2.24 |
| Price / Sales | 5.58 | — |
XFOR leads on 1 of 1 valuation factors.
Profitability
| AMGN | XFOR | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | — |
AMGN and XFOR split the profitability factors evenly.
Dividend
| AMGN | XFOR | |
|---|---|---|
| Dividend Yield | 2.56% | — |
| Payout Ratio | 62.61 | — |
AMGN and XFOR split the dividend factors evenly.
Risk & Sentiment
| AMGN | XFOR | |
|---|---|---|
| Short Interest | 1.66% | 0.08% |
XFOR leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, XFOR overview, XFOR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.